Precision AQ leadership expansion marks a strategic move to strengthen global AI, data strategy, evidence synthesis, and economic modelling capabilities. Precision AQ announced the appointment of two senior leaders to accelerate international growth and enhance AI-enabled, data-driven solutions for global biopharma partners.
As regulatory expectations evolve and real-world data volumes increase, life sciences companies need stronger evidence and smarter analytics. Therefore, Precision AQ is reinforcing its leadership team to help clients navigate market access complexity and Health Technology Appraisal (HTA) requirements.
Strengthening Evidence Synthesis and Economic Modelling
As part of the Precision AQ leadership expansion, Emma Hawe joins as Senior Vice President, Managing Director—Evidence Synthesis & Decision Modelling. She will lead evidence synthesis, advanced statistical analysis, and economic modelling within the Access Consulting and Health Economics and Outcomes Research (HEOR) teams.
Emma brings more than 25 years of experience in evidence generation and applied statistics. In addition, she currently serves as Chair of the HEOR Excellence—Methodology Award for The Professional Society for Health Economics and Outcomes Research (ISPOR).
Her expertise will support market access strategies by strengthening evidence packages used in HTA submissions and payer decision-making. Consequently, clients can improve their positioning in increasingly competitive global markets.
Advancing Data Strategy and AI Capabilities
Alongside Emma’s appointment, Yahya Anvar joins as Senior Vice President, Data Strategy & AI. Through this Precision AQ leadership expansion, he will enhance the company’s data infrastructure and scale AI-enabled delivery across business functions.
Yahya brings decades of experience in AI, advanced analytics, and enterprise data strategy across life sciences and healthcare. As a result, Precision AQ can translate complex data into actionable insights that drive faster and more precise commercial decisions.
Moreover, his leadership will help integrate AI across workflows, enabling scalable and insight-driven solutions for biopharma partners worldwide.
Accelerating Global Growth and Market Access Strategy
Together, the new leaders strengthen Precision AQ’s capabilities in analytics, technology, and evidence development. This Precision AQ leadership expansion also supports the company’s growing footprint in the European Union while reinforcing its global presence.
Jake Graetz, Chief Business Officer at Precision AQ, emphasized that access to innovation is never guaranteed. He noted that Emma’s expertise will help clients respond to evolving regulatory demands. At the same time, he highlighted that Yahya’s AI and data leadership will transform complex insights into scalable commercial solutions.
Ultimately, Precision AQ aims to deliver precise commercialization strategies that help biopharma companies succeed in dynamic global markets.
Read Also: Robo.ai Secures First Embodied AI Data Order for Robot Training
